Ad Header

PharmaLive

Slogan

The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Bay Area Startup BridgeBio Quietly Snags $135 Million From a Bunch of Wall Street Firms

BridgeBio Pharma, which was founded in 2015, recently closed on a $135 million series C round that was co-led by Viking Global Investors and KKR. They were joined by Perceptive Advisors, AIG, Aisling Capital, Cormorant Capital, and Janus Funds.

Read More »

Dupixent Takes Another Step Toward Blockbuster Status

On Sept. 11, 2017, Regeneron Pharmaceuticals and Sanofi announced positive data for its Phase III LIBERTY ASTHMA QUEST trial of Dupixent (dupilumab) in asthma. Investors and analysts do not seem to agree on whether dupilumab is on its way to being one of the biggest blockbuster drugs in the last two years, or if it’s the most overhyped drug on the market.

Read More »

Amicus Ends Lead Rare Disease Drug Program

Amicus Therapeutics terminated a late-stage wound-treatment therapeutic after it failed to meet primary and secondary endpoints in a Phase III trial.

Read More »

Purohit Navigation hires new VP, Brad Sherrill, for West Coast development

Purohit Navigation, a full-service healthcare communications and advertising agency, hired Brad Sherrill as Vice President of Account Services.

Read More »

Progress on global poverty and disease at risk, Gates says

Proposed United States budget cuts could put in jeopardy great progress in reducing global poverty and disease and lead to 5 million more deaths from AIDS alone, the philanthropist Bill Gates warned.

Read More »

Key U.S. senators reach deal on funding children’s health program

Leaders of the U.S. Senate Finance Committee said they reached an agreement to finance a federal insurance program for millions of lower-income children and pregnant women that was due to expire at the end of September 2017.

Read More »

Mylan says Allergan misusing tribal sovereignty in patent dispute

Generic drugmaker Mylan NV alleged in a court filing that rival Allergan Plc is trying to take advantage of Native American sovereignty to shield its patent for the blockbuster dry-eye treatment Restasis.

Read More »

Texas calls in U.S. Air Force to counter post-storm surge in mosquitoes

Texas launched aerial attacks on mosquitoes swarming coastal regions of the state and threatening to spread disease and hinder disaster recovery in the aftermath of Hurricane Harvey.

Read More »

Vertex Ends Phase II CF Trial

Vertex Pharmaceuticals reportedly terminated a long-acting trial combining a recently acquired therapy with the company’s cystic fibrosis drug Kalydeco.

Read More »

Sage’s seizure drug fails key trial

Sage Therapeutics Inc.’s shares tumbled 23 percent after its drug to treat a life-threatening seizure disorder failed to meet the main goal of a key trial.

Read More »

Ad Right Top

MedAdNews

Extensive pharmaceutical business and marketing intelligence. For back issues, please contact MDAD@kmpsgroup.com.

June 2019 Focus: Payer access, biotech/biopharma, DTC, rare diseases, and more!

Subscribe

Ad Right Bottom